A constitutively high basal level of autophagy is demonstrated in TNBC cells, which might contribute to their relatively lower sensitivity to radiation-induced cell death and to the driving forces in acquiring radioresistance.
Abstract
Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC) with higher incidence rates in India. Ionizing radiation (IR) is a key component of TNBC treatment regimens. However, overall suboptimal response during the course of multiple repeat radiotherapy with eventual attainment of radioresistance remains a major challenge for this oncologic treatment modality. To overcome this limitation, it is important to understand molecular signatures that drive cells to transform into non-responsive populations against radiation therapy. Here, we demonstrate a constitutively high basal level of autophagy in TNBC cells, which might contribute to their relatively lower sensitivity to radiation-induced cell death. We also observed an elevated level of p62 in TNBC cells, which is regulated independently of autophagic flux. Concurrent upregulation of p62 and basal level of autophagy were found to be the driving forces in acquiring radioresistance in breast cancer cells. Ectopic expression of p62 enabled breast cancer cells to proliferate rapidly with enhanced migration potential. Reciprocally, posttranscriptional or pharmacological inhibition of p62 prevented the proliferation and migration potential of TNBC cells. Our high-throughput next-generation sequencing (NGS) data revealed VCAM-1 as a key mediator in p62-driven cell proliferation and acquired radioresistance. Likewise, impairment of autophagic flux, either by pharmacological inhibitors (CQ and bafA1) or by genetic deletion of ATG5, led to reversal of radioresistance. Collectively, our data highlight that an elevated basal level of autophagy with co-induction of p62 de novo protein synthesis confers radioresistance in TNBC.
Background: Triple-negative breast cancer (TNBC) is exceptionally aggressive, with a high recurrence rate, resistance to chemotherapy, and a tendency to metastasize. The long non-coding RNA growth arrest-specific 5 (GAS5) is associated with TNBC progression; however, the specific mechanism still requires further explor...
Jun-Ze Du, Xin He, Ling-Feng Tang et al.· Cancers· 0 citations
RIPK3 enhances the sensitivity of colorectal cancer cells to 5-FU and increases the efficacy of 5-FU in inhibiting cell proliferation, invasion, and migration by activating cellular autophagy through inhibition of the AKT-mTOR signaling pathway, thereby reversing drug resistance in colorectal cancer cells.
Biao Wang, Xiao-Tong An, Wei-Hua Fu· Scientific Reports· 0 citations
A novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers is suggested, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development.
Jin-Chen Wang, Wei Wang, Jun-Jie Hu et al.· Asia-Pacific Journal of Clin...· 0 citations
Triple negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Conventional treatments include neoadjuvant chemo-immunotherapy followed by surgical resection and may include further adjuvant immunotherapy and/or radiotherapy of the tumor bed and lymph nodes. Nonetheless, TNBC patients w...
Steven W. Wall, Karen Wang, A. Greer et al.· bioRxiv· 0 citations
The CD24-EDN1-NFκB axis has a crucial role in PTX resistance in TNBC, according to this study, offering a new therapeutic target for treating chemotherapy resistance.
Ying-Cheng Deng, Jun-Jie Tian, Li-Jun Zhang et al.· Biochimica et Biophysica Act...· 0 citations
Allicin acts as a pro-oxidant, regulating programmed cell death pathways in BT-549 cancer cells through ROS signaling, and the involvement of reactive oxygen species in regulating these signaling pathways is indicated.
Omniah A. Mansouri, Tahani Bakhsh· Journal of King Saud Univers...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.